AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3314973 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir 400 mg and Placebo
Number of subjects: 60
Study 30029153 — intervention group
Group type: EXPERIMENTAL
Intervention: No Exercise Group (n=19)
Number of subjects: 57
Study 30029153 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced MVPA Group (n=18)
Number of subjects: 57
Study 30029153 — intervention group
Group type: COMPARATOR
Intervention: Control Group (n=20)
Number of subjects: 57
Study 27766413 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 1044
Study 27766413 — intervention group
Group type: COMPARATOR
Intervention: Converted laparoscopic surgery
Number of subjects: 1044
Study 27766413 — intervention group
Group type: COMPARATOR
Intervention: Converted procedures
Number of subjects: 1044
Study 25996491 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary IOL implantation
Number of subjects: 114
Study 25996491 — intervention group
Group type: COMPARATOR
Intervention: Contact lens (no IOL implantation)
Number of subjects: 114
Study 25996491 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger age at surgery
Number of subjects: 114
Study 25996491 — intervention group
Group type: EXPERIMENTAL
Intervention: Smaller corneal diameter
Number of subjects: 114
Study 23937975 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepped-care programme (watchful waiting, guided self-help, problem solving treatment, referral to general practitioner)
Number of subjects: 230
Study 20562124 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (n = 40), administered three times a week for 2 years
Number of subjects: 83
Study 20562124 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (n = 40)
Number of subjects: 83
Study 20562124 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label azithromycin for BOS
Number of subjects: 83
Study 20562124 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 43)
Number of subjects: 83
Study 19040726 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% tea tree oil (TTO) body wash
Number of subjects: 0
Study 19040726 — intervention group
Group type: COMPARATOR
Intervention: Standard body wash (Johnsons Baby Softwash)
Number of subjects: 0
Study 16507189 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation induction with sevoflurane followed by subhypnotic dose of propofol (1 mg kg‐1)
Number of subjects: 120
Study 16507189 — intervention group
Group type: COMPARATOR
Intervention: Intravenous propofol induction
Number of subjects: 120
Study 16507189 — intervention group
Group type: COMPARATOR
Intervention: Inhalation induction with sevoflurane
Number of subjects: 120
Study 12748506 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrauterine growth restriction (IUGR) fetuses
Number of subjects: 0
Study 12748506 — intervention group
Group type: COMPARATOR
Intervention: Non-IUGR fetuses
Number of subjects: 0
Study 11055098 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc nasal gel (Zicam)
Number of subjects: 213
Study 11055098 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 213
Study 8927940 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified-release amoxicillin tablet
Number of subjects: 6
Study 8927940 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablet
Number of subjects: 6
Study 1581716 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 29
Study 1581716 — intervention group
Group type: COMPARATOR
Intervention: Pindolol
Number of subjects: 29
Study 31387970 — intervention group
Group type: EXPERIMENTAL
Intervention: Outreach plus $5 incentive
Number of subjects: 8565
Study 31387970 — intervention group
Group type: EXPERIMENTAL
Intervention: Outreach plus $10 incentive
Number of subjects: 8565
Study 31387970 — intervention group
Group type: EXPERIMENTAL
Intervention: Any incentive (combined $5 and $10)
Number of subjects: 8565
Study 31387970 — intervention group
Group type: COMPARATOR
Intervention: Outreach alone
Number of subjects: 8565
Study 31387970 — intervention group
Group type: COMPARATOR
Intervention: No incentives
Number of subjects: 8565
Study 28931127 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 standard dose IM dose of PVRV
Number of subjects: 30
Study 28931127 — intervention group
Group type: EXPERIMENTAL
Intervention: 1/5th‐fractional dose ID of PVRV
Number of subjects: 30
Study 28931127 — intervention group
Group type: EXPERIMENTAL
Intervention: 2/5th‐fractional dose ID of PVRV
Number of subjects: 30
Study 28931127 — intervention group
Group type: EXPERIMENTAL
Intervention: 3/5th‐fractional dose ID of PVRV
Number of subjects: 30
Study 28931127 — intervention group
Group type: COMPARATOR
Intervention: All groups after simulated rabies post-exposure prophylaxis (D0, D3) 1 year later
Number of subjects: 30
Study 26947254 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotion regulation training (n = 25)
Number of subjects: 48
Study 26947254 — intervention group
Group type: COMPARATOR
Intervention: No-regulation group (n = 23)
Number of subjects: 48
Study 25055554 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ozone therapy and small doses of direct current (20-25mkA)
Number of subjects: 89
Study 22582168 — intervention group
Group type: EXPERIMENTAL
Intervention: Model of continuous and variable resource allocation in VSTM
Number of subjects: 0
Study 22582168 — intervention group
Group type: COMPARATOR
Intervention: Previous models of VSTM (slot models)
Number of subjects: 0
Study 19225062 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine 5'-monophosphate (AMP)
Number of subjects: 31
Study 19225062 — intervention group
Group type: EXPERIMENTAL
Intervention: Methacholine
Number of subjects: 31
Study 19225062 — intervention group
Group type: COMPARATOR
Intervention: Exhaled nitric oxide (ENO)
Number of subjects: 31
Study 19225062 — intervention group
Group type: COMPARATOR
Intervention: Exhaled breath condensate (EBC) pH
Number of subjects: 31
Study 18953411 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate and delayed reaching tasks under non‐masked trials
Number of subjects: 0
Study 18953411 — intervention group
Group type: COMPARATOR
Intervention: Immediate and delayed reaching tasks under masked trials
Number of subjects: 0
Study 18953411 — intervention group
Group type: EXPERIMENTAL
Intervention: Non‐masked trials
Number of subjects: 0
Study 18953411 — intervention group
Group type: COMPARATOR
Intervention: Masked trials
Number of subjects: 0
Study 18953411 — intervention group
Group type: EXPERIMENTAL
Intervention: Reaching tasks
Number of subjects: 0
Study 16186468 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment with aspirin alone
Number of subjects: 84
Study 16186468 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional treatment plus colchicine (1.0-2.0 mg the first day and then 0.5-1.0 mg/d for 6 months)
Number of subjects: 84
Study 12618568 — intervention group
Group type: EXPERIMENTAL
Intervention: rest and cuff occlusion with relaxation
Number of subjects: 16
Study 12618568 — intervention group
Group type: EXPERIMENTAL
Intervention: relaxation alone
Number of subjects: 16
Study 12618568 — intervention group
Group type: EXPERIMENTAL
Intervention: relaxation
Number of subjects: 16
Study 12618568 — intervention group
Group type: EXPERIMENTAL
Intervention: PECO with relaxation
Number of subjects: 16
Study 12618568 — intervention group
Group type: COMPARATOR
Intervention: PECO
Number of subjects: 16
Study 10229137 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual oscillation technique applied at T12 and L4 for 12 minutes
Number of subjects: 30
Study 10229137 — intervention group
Group type: COMPARATOR
Intervention: Resting
Number of subjects: 30
Study 8764423 — intervention group
Group type: EXPERIMENTAL
Intervention: Macaine (Keatings)
Number of subjects: 104
Study 8764423 — intervention group
Group type: COMPARATOR
Intervention: Regibloc (Intramed)
Number of subjects: 104
Study 1906935 — intervention group
Group type: COMPARATOR
Intervention: Gold sodium thiomalate (GSTM) 50 mg intramuscularly for 6 months
Number of subjects: 57
Study 1906935 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) 15 mg intramuscularly for 6 months
Number of subjects: 57
Study 6600579 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin ethylsuccinate (40 mg/kg/day every six hours for seven days)
Number of subjects: 27
Study 6600579 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 27
Study 6600579 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin ethylsuccinate
Number of subjects: 27
Study 30165750 — intervention group
Group type: EXPERIMENTAL
Intervention: Clemastine 2 mg (1 mg/ml)
Number of subjects: 20
Study 30165750 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline 2 ml)
Number of subjects: 20
Study 28296735 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil (infused at 0.1 μg/kg/min with demand boluses of 0.1 μg/kg)
Number of subjects: 144
Study 28296735 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 144
Study 28296735 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 144
Study 28296735 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study 28296735 — intervention group
Group type: COMPARATOR
Intervention: Remifentanil and Placebo
Number of subjects: 144
Study 27012255 — intervention group
Group type: EXPERIMENTAL
Intervention: Choice condition (parent training program options)
Number of subjects: 129
Study 27012255 — intervention group
Group type: COMPARATOR
Intervention: No-choice condition (parent training program options)
Number of subjects: 129
Study 27012255 — intervention group
Group type: EXPERIMENTAL
Intervention: In-home treatment (preferred modality in choice condition)
Number of subjects: 129
Study 27012255 — intervention group
Group type: EXPERIMENTAL
Intervention: Group and clinic modalities (across conditions)
Number of subjects: 129
Study 24525810 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (20 mg daily)
Number of subjects: 601
Study 24525810 — intervention group
Group type: COMPARATOR
Intervention: Reboxetine (4 mg twice daily)
Number of subjects: 601
Study 24525810 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram and Reboxetine
Number of subjects: 601
Study 22653993 — intervention group
Group type: EXPERIMENTAL
Intervention: RISE-95 test (ramp-incremental step-exercise test)
Number of subjects: 24
Study 19682128 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants in the trial
Number of subjects: 1105
Study 19682128 — intervention group
Group type: COMPARATOR
Intervention: Nonresponding nonparticipants
Number of subjects: 1105
Study 17973732 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (noise assessments, educational sessions, mailed reminders with brochures, placement of hearing protection)
Number of subjects: 25
Study 17973732 — intervention group
Group type: COMPARATOR
Intervention: Comparison (no specific intervention mentioned)
Number of subjects: 25
Study 15365306 — intervention group
Group type: EXPERIMENTAL
Intervention: Injectable naltrexone (400 mg, administered intramuscularly once every 28 days for 4 months)
Number of subjects: 30
Study 15365306 — intervention group
Group type: COMPARATOR
Intervention: Placebo injection (matching to naltrexone, administered once every 28 days for 4 months)
Number of subjects: 30
Study 15365306 — intervention group
Group type: EXPERIMENTAL
Intervention: Injectable naltrexone
Number of subjects: 30
Study 11226444 — intervention group
Group type: EXPERIMENTAL
Intervention: Constant 17beta‐estradiol (E2), 1 mg, plus intermittent norgestimate (NGM) 90 microg (3 days off, 3 days on)
Number of subjects: 438
Study 11226444 — intervention group
Group type: COMPARATOR
Intervention: E2 2 mg/norethisterone acetate (NETA) 1 mg
Number of subjects: 438
Study 9678315 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical diagnosis of Lewy body disease
Number of subjects: 105
Study 9678315 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical diagnosis of Parkinson disease (PD)
Number of subjects: 105
Study 9678315 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical diagnosis of dementia with Lewy bodies (DLB)
Number of subjects: 105
Study 9678315 — intervention group
Group type: COMPARATOR
Intervention: Raters' results compared to primary neurologists
Number of subjects: 105
Study 7986315 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin 2.5 mg q.p.m.
Number of subjects: 429
Study 7986315 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin 5 mg q.p.m.
Number of subjects: 429
Study 7986315 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin 10 mg q.p.m.
Number of subjects: 429
Study 7986315 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin 20 mg q.p.m.
Number of subjects: 429
Study 7986315 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 429
Study 2532801 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative irradiation (27 Gy) combined with local microwave hyperthermia
Number of subjects: 0
Study 2532801 — intervention group
Group type: COMPARATOR
Intervention: Preoperative irradiation (27 Gy) alone
Number of subjects: 0
Study 30982442 — intervention group
Group type: EXPERIMENTAL
Intervention: Astaxanthin supplementation
Number of subjects: 9
Study 30982442 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose astaxanthin (≥20 mg/day)
Number of subjects: 9
Study 30982442 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose astaxanthin (<20 mg/day)
Number of subjects: 9
Study 31081140 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrauterine tamponade
Number of subjects: 20060
Study 31081140 — intervention group
Group type: EXPERIMENTAL
Intervention: Hysterectomy
Number of subjects: 20060
Study 31081140 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparotomy
Number of subjects: 20060
Study 28043661 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive mechanical ventilation (MV)
Number of subjects: 219
Study 28043661 — intervention group
Group type: COMPARATOR
Intervention: Non-invasive ventilation (NIV)
Number of subjects: 219
Study 26003264 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological intervention (group sessions, once a week for 5 weeks)
Number of subjects: 54
Study 26003264 — intervention group
Group type: COMPARATOR
Intervention: Usual treatment (including dietary advice)
Number of subjects: 54
Study 23305646 — intervention group
Group type: EXPERIMENTAL
Intervention: GcgR agonist
Number of subjects: 2
Study 23305646 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural glucagon injection
Number of subjects: 2
Study 23305646 — intervention group
Group type: EXPERIMENTAL
Intervention: GcgR activation in WT mice
Number of subjects: 2
Study 23305646 — intervention group
Group type: EXPERIMENTAL
Intervention: GcgR activation in FGF21 knockout mice
Number of subjects: 2
Study 21501887 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus 0.1% ointment
Number of subjects: 30
Study 21501887 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 30
Study 18274899 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS-guided propofol sedation
Number of subjects: 44
Study 18274899 — intervention group
Group type: COMPARATOR
Intervention: Standard propofol sedation
Number of subjects: 44
Study 16446191 — intervention group
Group type: EXPERIMENTAL
Intervention: Biodegradable restrictor
Number of subjects: 32
Study 16446191 — intervention group
Group type: COMPARATOR
Intervention: UHMWPE restrictor
Number of subjects: 32
Study 12867397 — intervention group
Group type: EXPERIMENTAL
Intervention: Artisan Hyperopia phakic intraocular lens (IOL; model 203W; Ophtec, Groningen, The Netherlands) implanted in patients with hypermetropia.
Number of subjects: 26
Study 10390394 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP), 1,000 micrograms twice a day
Number of subjects: 23
Study 10390394 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (BUD), 800 micrograms twice a day
Number of subjects: 23
Study 10390394 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 10390394 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP), 200 micrograms twice a day
Number of subjects: 23
Study 10390394 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (BUD), 200 micrograms twice a day
Number of subjects: 23
Study 8656545 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal lidocaine
Number of subjects: 81
Study 8656545 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 81
Study 2067759 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium pyrrolidone carboxylic acid (360 mg Mg) administered three times a day from the 15th day of the menstrual cycle to the onset of menstrual flow
Number of subjects: 32
Study 2067759 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered three times a day from the 15th day of the menstrual cycle to the onset of menstrual flow
Number of subjects: 32
Study 6336937 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular cephaloridine (three 1-g perioperative doses)
Number of subjects: 123
Study 6336937 — intervention group
Group type: COMPARATOR
Intervention: Oral erythromycin base and neomycin sulfate (three 1-g preoperative doses)
Number of subjects: 123
Study 31560027 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive resistance training 3 days/week for 12 weeks
Number of subjects: 70
Study 29596045 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual‐assisted face‐to‐face Positive Behaviour Support (PBS) training
Number of subjects: 246
Study 29596045 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 246
Study 29596045 — intervention group
Group type: EXPERIMENTAL
Intervention: PBS training
Number of subjects: 246
Study 28051337 — intervention group
Group type: EXPERIMENTAL
Intervention: Trauma-Focused Cognitive-Behavioral Therapy (TF-CBT) for 12 sessions (n=40)
Number of subjects: 84
Study 28051337 — intervention group
Group type: COMPARATOR
Intervention: Waitlist (WL) condition (n=44)
Number of subjects: 84
Study 26695667 — intervention group
Group type: EXPERIMENTAL
Intervention: PCT group (antibiotic therapy guided by serum procalcitonin)
Number of subjects: 396
Study 26695667 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard therapy according to clinical guidance)
Number of subjects: 396
Study 24252418 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (VAS)
Number of subjects: 263
Study 24252418 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (VAS) for males
Number of subjects: 263
Study 24252418 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (VAS) for females
Number of subjects: 263
Study 24252418 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 263
Study 21255035 — intervention group
Group type: EXPERIMENTAL
Intervention: omalizumab
Number of subjects: 400
Study 21255035 — intervention group
Group type: COMPARATOR
Intervention: OAT
Number of subjects: 400
Study 18448301 — intervention group
Group type: EXPERIMENTAL
Intervention: Navigator setting under the left hepatic lobe
Number of subjects: 50
Study 18448301 — intervention group
Group type: COMPARATOR
Intervention: Navigator setting on the right diaphragm
Number of subjects: 50
Study 16788393 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency cranial electrostimulation, 30 mins/day, 5 days/week, for 6 weeks
Number of subjects: 21
Study 16788393 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 21
Study 12671541 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflavone supplement (100 mg daily)
Number of subjects: 30
Study 12671541 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 11269917 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA cream (2.5% lidocaine and 2.5% prilocaine in oil emulsion) applied 2 hours prior to microneurography
Number of subjects: 10
Study 11269917 — intervention group
Group type: COMPARATOR
Intervention: Aqueous placebo cream applied 2 hours prior to microneurography
Number of subjects: 10
Study 9408797 — intervention group
Group type: EXPERIMENTAL
Intervention: Dichotic listening under divided attention condition
Number of subjects: 16
Study 9408797 — intervention group
Group type: EXPERIMENTAL
Intervention: Dichotic listening under focused attention condition 1
Number of subjects: 16
Study 9408797 — intervention group
Group type: EXPERIMENTAL
Intervention: Dichotic listening under focused attention condition 2
Number of subjects: 16
Study 8147088 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex physical therapy (CPT) including special lymphatic massage after surgical reconstruction
Number of subjects: 0
Study 8147088 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex physical therapy (CPT)
Number of subjects: 0
Study 3524119 — intervention group
Group type: EXPERIMENTAL
Intervention: Desenkephalin-gamma-endorphin (3 mg)
Number of subjects: 44
Study 3524119 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceruletide (40 micrograms)
Number of subjects: 44
Study 3524119 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 29055287 — intervention group
Group type: EXPERIMENTAL
Intervention: 7630 (Pelargonium extract)
Number of subjects: 207
Study 29055287 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 207
Study 27511342 — intervention group
Group type: EXPERIMENTAL
Intervention: Transtheoretical model-based individual counseling and training (5 interviews over 6 months)
Number of subjects: 77
Study 27511342 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 77
Study 24630510 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecystectomy after endoscopic sphincterotomy (ES)
Number of subjects: 162
Study 24630510 — intervention group
Group type: COMPARATOR
Intervention: Wait-and-see policy (conservative management) after ES
Number of subjects: 162
Study 23946347 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.3 g/d oat β-glucans for 3 weeks
Number of subjects: 14
Study 23946347 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.3 g/d oat β-glucans
Number of subjects: 14
Study 23946347 — intervention group
Group type: COMPARATOR
Intervention: Control (no β-glucans)
Number of subjects: 14
Study 21118514 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive education on lifestyle improvement related to type 2 diabetes by registered dietitians in clinics.
Number of subjects: 200
Study 21118514 — intervention group
Group type: COMPARATOR
Intervention: Standard advice on glycemic control by registered dietitians.
Number of subjects: 200